Medications for Glycogen Storage Disease Type Ii

3 results

Lumizyme (alglucosidase alfa)

(ALGLUCOSIDASE ALFA)
Genzyme Corporation
Usage: LUMIZYME® is indicated for the treatment of Pompe disease, which is caused by acid α-glucosidase (GAA) deficiency.

Nexviazyme (avalglucosidase alfa)

(avalglucosidase alfa)
Genzyme Corporation
Usage: NEXVIAZYME is indicated for treating late-onset Pompe disease in patients aged 1 year and older, specifically for those with lysosomal acid alpha-glucosidase (GAA) deficiency.

Pombiliti (cipaglucosidase alfa-atga)

(cipaglucosidase alfa-atga)
AMICUS THERAPEUTICS US, LLC
Usage: POMBILITI, in combination with Opfolda, is indicated for adult patients weighing ≥40 kg with late-onset Pompe disease (GAA deficiency) who have not shown improvement on current enzyme replacement therapy (ERT).